FAKTOR-OPTIONSSCHEIN - MODERNA | Delayed Deutsche Boerse AG 03:51:00 2024-05-17 pm EDT | ||
| 0.54 EUR | 0.00% |
|
| Current month | -53.45% | ||
| 1 month | -63.27% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 0.54 | 0.00% |
| 24-05-16 | 0.54 | -10.00% |
| 24-05-15 | 0.6 | 0.00% |
| 24-05-14 | 0.6 | -9.09% |
| 24-05-13 | 0.66 | -19.51% |
Delayed Quote Deutsche Boerse AG
Last update May 17, 2024 at 03:51 pm EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| WKN | SF4DZ9 |
| ISIN | DE000SF4DZ99 |
| Date issued | 2021-09-10 |
| Strike | 422.8 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 25.12 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 102.1 € |
|---|---|
| Lowest since issue | 0.53 € |
| Spread | 0.01 € |
| Spread % | 1.82% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
132.9
USD
Average target price
138.5
USD
Spread / Average Target
+4.22%
- Stock Market
- Certificates
- Certificat
